Loading...
CannBioRx Life Sciences Corp.
ATNFW•NASDAQ
HealthcareMedical - Pharmaceuticals
$0.008
$0.00(2.53%)
CannBioRx Life Sciences Corp. (ATNFW) Stock Overview
Explore CannBioRx Life Sciences Corp.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for ATNFWStats details for ATNFW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ATNFWAnalyst Recommendations details for ATNFW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
CEO
Mr. Lloyd Blair Jordan L.L.B., M.B.A.
Employees
4
Headquarters
Building 4, Palo Alto, DE
Founded
1970